Industry
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Loading...
Open
8.58
Mkt cap
301M
Volume
1M
High
8.58
P/E Ratio
-2.90
52-wk high
18.75
Low
7.99
Div yield
N/A
52-wk low
7.99
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 2:38 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
July 08, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:16 am
Portfolio Pulse from Avi Kapoor
May 10, 2024 | 4:44 pm
Portfolio Pulse from Benzinga Insights
May 10, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
May 10, 2024 | 2:48 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.